Currently, there are several ongoing, randomized placebo-control trials in patients with and without T2D after admission for HF, evaluating the clinical benefit and safety of in-hospital use of SGLT2 inhibitors: empagliflozin (EMPULSE) [23], and dapagliflozin (DAPA ACT HF-TIMI 68 [24] and Dapagliflozin Heart Failure Readmission [25]). The gene discussed is SLC5A2; the disease is hydrops fetalis.